Key result
Oral PCSK9 inhibitors reduce LDL-C by up to ~60% versus placebo across clinical trials.
Why the study?
Oral PCSK9 inhibitors combine the potency of injectable PCSK9 inhibitors with the convenience of oral administration, but their clinical development and implementation require review.
Do oral PCSK9 inhibitors effectively reduce LDL-C levels?
Do oral PCSK9 inhibitors effectively reduce LDL-C levels?
Answers are grounded in this paper and cite their sources.
Oral PCSK9 inhibitors demonstrate significant LDL-C lowering efficacy in early and late-phase trials, offering a convenient alternative to injectable therapies.
PURPOSE OF REVIEW: Oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a new generation of lipid-lowering therapies that combine the potency of injectable PCSK9 inhibitors with the convenience of oral administration. This review examines the mechanisms, trial evidence, and implementation considerations for oral PCSK9 inhibitors that have reached phase 2 or later clinical development. RECENT FINDINGS: Two oral PCSK9 inhibitors, enlicitide and laroprovstat, have demonstrated that oral PCSK9 inhibition is pharmacologically viable through distinct mechanisms of action. Enlicitide, a macrocyclic peptide that competitively blocks the PCSK9-LDL receptor interaction, achieved placebo-corrected LDL-C reductions of ~60% across three phase 3 trials, with high adherence and a favorable safety profile over 52weeks. Laroprovstat, a small molecule that inhibits PCSK9-mediated lysosomal trafficking of the LDL receptor, produced dose-dependent LDL-C reductions of up to 51% in a phase 2 trial and is advancing through phase 3 evaluation. Large cardiovascular outcomes trials remain underway for both agents. SUMMARY: Oral PCSK9 inhibitors have the potential to improve the convenience and acceptability of PCSK9-targeted therapy. Whether these advantages translate into greater real-world uptake will depend on affordability, payer coverage, clinician adoption, and long-term adherence.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2026) conducted a review in Hyperlipidemia. Oral PCSK9 inhibitors (enlicitide and laroprovstat) vs. Placebo was evaluated. Oral PCSK9 inhibitors enlicitide and laroprovstat achieved placebo-corrected LDL-C reductions of approximately 60% and up to 51%, respectively, in phase 2 and 3 clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: